ESMO 2023 – Padcev hits its home run
The presidential session heralds a combo of Padcev and Keytruda as the new front-line bladder cancer standard of care.
Triple meeting 2023 – PRMT5 has a wobble
Initial data on Amgen’s AMG 193 give some Tango investors a headache.
Bristol puts Mirati out of its misery
The acquisition brings closure for Mirati at last, though some investors will feel disappointed.
Three mystery phase 1 entrants
Bristol, AbbVie and Jiangsu HengRui move to enter clinical trials with undisclosed mechanisms of action.
